Nucleic Acid Therapeutics Market Research, 2031
The global nucleic acid therapeutics market was valued at $4.1 billion in 2021, and is projected to reach $12.2 billion by 2031, growing at a CAGR of 11.6% from 2022 to 2031.
The genetic material is composed of naturally occurring chemicals called nucleic acids, which are also the principal information-carrying molecules in cells. Deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and synthetic nucleic acid are the three different forms of nucleic acids. Endogenous nucleic acids are conceded by Watson-Crick base pairing in a sequence-specific way, mediating their universal mode of action. Numerous chronic diseases are treated with medicines based on nucleic acids. It demonstrates the important therapeutic impact on long-term conditions, such cancer, tumors, diabetes, TB, and AIDS. For instance, the nucleic acid therapeutics market has received a lot of interest recently as it shows significant effects in chronic disease treatments.
The nucleic acid therapeutics market is expected to grow quickly as a result of the numerous innovative therapies that are now undergoing approval and development. The growth of the pharmaceutical and healthcare sectors, creation of biological goods, and DNA therapies all contribute to the rise of the nucleic acid therapeutics market. On the other side, the development of the global nucleic acid therapies market is expected to be constrained by lack of experience, lack of technologies, and their high cost. As both, developed and emerging nations play a significant role in the analysis and development of new therapies, the market is likely to continue to expand in the future. The high cost of research and development, as well as costly therapies and technologies, are some of the key factors limiting industry expansion. Additional factors that are boosting the market expansion for nucleic acid therapeutics globally include, speedier absorption and quicker market access, strong product demand, and a greater concentration of pharmaceutical companies on the development of treatments for nucleic acid therapeutics. The factors that are anticipated to impede the growth of the global nucleic acid therapeutics market during the forecast period include, absence of alternative treatments for a variety of chronic conditions, accessibility of medicines, and high diagnostic costs. The growth of the nucleic acid therapeutics market is driven by increased research & development of new medicines and therapies and increased disease prevalence.
Impact of COVID-19 on the Market
Coronavirus Severe acute respiration syndrome (SARS-CoV-2) is an infectious disease caused by the novel coronavirus (COVID-19), which originated in the Wuhan district in China in the late 2019, and since has spread to 212 countries. The virus was initially referred to as “novel coronavirus 2019” (2019-nCoV) by the WHO, However, on February 11, 2020, it was given the official name of SARS-CoV-2 by the International Committee on Taxonomy of Viruses. WHO declared COVID-19 as pandemic on March 11, 2020, and by September 1, 2020, over 28.1 million people have been infected globally with over 909,000 deaths. COVID-19 symptoms include fever, cough, and shortness of breath.
Nearly all industries have been impacted by the global public health pandemic, COVID-19. As coronavirus crises sweep the globe and force healthcare organizations to devote the majority of their funds to fight COVID-19, it has also resulted in a significant decline in demand for the nucleic acid therapeutics market across several sectors, particularly the health and pharmaceutical sectors. The main cause of the interruptions experienced by patients getting treatment for nucleic acid therapeutics in hospitals was the risk of infection. The treatments based on nucleic acid require hospitalization, hence the market growth declined during this period. As a result, the COVID-19 outbreak slowed down the global market growth for treatments of nucleic acid therapeutics, which was expected to have a negative effect on the market's value in 2021 and beyond.
The nucleic acid therapeutics market is segmented into Products, Application and End User.
The nucleic acid therapeutics market size is segmented on the basis of type of products, application, end user, and region. By type of product, it is segmented into anti-sense oligonucleotides (ASOs) and DNA aptamers, RNA interference [RNAi] and short interfering RNAs [siRNAs], and others. By application, the market is bifurcated into monogenetic disorders and multi-genetic disorders. By end user, the market is fragmented into hospitals & clinics and academic & research institutes.
Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
By Products
RNA interference [RNAi] and short interfering RNAs [siRNAs] segment held a dominant position in 2021 and would continue to maintain the lead over the forecast period.
By Product Segment Review
By product, the RNA interference [RNAi] and short interfering RNAs [siRNAs] segment was the highest revenue contributor to the nucleic acid therapeutics market share in 2021. The growth of this segment increasing owing to, Givosiran approval by FDA in November 2019. Other products from this segment, such as anti-sense oligonucleotides (ASOs) and DNA aptamers also contribute in the market growth. Moreover, the growth of market is driven by increasing chronic diseases and new medications are being approved.
[APPLICATIONGRAPH]
By Application Segment Review
By application, in nucleic acid therapeutics market size, the monogenetic disorders segment was the highest revenue contributor to the market in 2021, due to majority of the diseases treated by nucleic acid therapeutics, which are inherited and are highly prevalent. The major nucleic acid therapeutics market growth is due to newly developed and approved therapies by the industry leaders to treat single gene defects. In multi-genetic disorders, the industry leaders are focusing on developing new techniques to overcome drawbacks, such as off-targets, stability, and quality of genes.
By End User
Hospitals and Clinics segment is projected as one of the most lucrative segment.
By End User Segment Review
By end user, the market is classified into hospitals & clinics and academic & research institutes. The hospitals & clinics segment was the highest revenue contributor to the market in 2021. Hospitals and clinics are the most reliable as they ensure the treatment given to the patient, under expertise, equipped techniques, and thorough patient care. Hence, patients prefer this segment.
By Region
North America segment is projected as one of the most lucrative segment.
Region Type Segment Review
Region-wise, in nucleic acid therapeutics industry, North America was the highest revenue contributor in 2021, owing to increasing approvals of novel nucleic acid treatments and availability of nucleic acid extraction technology. Due to availability of all favorable factors, the market growth of this region is at the peak and is expected to remain the same during the forecast period.
Major key players that operate in the global nucleic acid therapeutics industry are Agilent Technologies Inc., Alnylam Pharmaceuticals, Inc., Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals, Benetic Biopharma, Inc., Caperna Inc. [Moderna], Copernicus Therapeutics, Genzyme (Sanofi), Ionis Pharmaceuticals, MERCK KGAA, Novartis AG, Phylogica, Protagonist Therapeutics, QIAGEN N.V., Sarepta Therapeutics, Silence Therapeutics plc., and Thermo Fisher Scientific Inc.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the nucleic acid therapeutics market analysis from 2021 to 2031 to identify the prevailing nucleic acid therapeutics market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the nucleic acid therapeutics market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global nucleic acid therapeutics market trends, key players, market segments, application areas, and market growth strategies.
Nucleic Acid Therapeutics Market Report Highlights
| Aspects | Details |
 Market Size By 2031 | USD 12.2 billion |
 Growth Rate | CAGR of 11.6% |
 Forecast period | 2021 - 2031 |
 Report Pages | 315 |
 By Products |
|
 By Application |
|
 By End User |
|
 By Region |
|
 Key Market Players | Protagonist Therapeutics, Benitec Biopharma, NOVARTIS AG., Merck KGaA, Qaigen NV, Arbutus Biopharma, Sarpeta Therapeutics, Silence Therapeutics, Agilent Technologies, Genzyme Sanofi, Copernicus, Thermo Fisher Scientific Inc. |
Analyst Review
The nucleic acid therapeutics shows significant effects in various chronic diseases, such as cancer, tuberculosis, diabetes, AIDS, muscular dystrophy, and in cardiovascular diseases. Furthermore, the increasing demand for the treatment of various illnesses highlighted the nucleic acid therapeutics market. The nucleic acid therapeutics suppress the protein translation by acting on mRNA. This suppression results into decreased unwanted growth of proteins, which forms the DNA molecule. The suppression of DNA is expected to help avoid unwanted genetic changes resulting in minimized disease spread. The various category of nucleic acid therapeutics, such as anti-sense oligonucleotides (ASOS) and DNA aptamers shows significant results in chronic disease. The ASOS act by binding to target molecule through hydrogen binding, resulting into reduced nuclease degradation, increased stability, and lowered dissociation rate. Moreover, aptamers are progressively used for novel drug delivery treatments in tumors to target the tumor cells and in malignancy as an anticancer molecule. The market of nucleic acid therapeutics is projected to increase in terms of treatment offering due to strong emerging pipeline. The nucleic acid therapeutics are applicable in monogenetic and multi-genetic diseases. They work by decreasing the expression of toxic genes. For instance, the increasing development and urge for prompt treatment are expected to propel the market growth during the forecast period.
Pharmaceutical industry key players attention has moved to the developing of new novel therapies of nucleic acids. The anti-sense oligonucleotides (ASOS) and DNA aptamers is the major revenue generating products segment in the market. The ASOS shows significant action in the treatment of tumor and cancer. The pharmaceutical companies are involved majorly in finding new biological treatments. The leaders of industry are focused on finding new research methodology to understand the human genome, finding best therapies with prompt therapeutic actions. The revenue growth of the market is driven by the development of new gene therapies, emerging pipeline of novel therapies, and increased prevalence of chronic conditions. For instance, the market growth is accelerating and is expected to remain the same during the forecast period.
Rise in chronic disease conditions, speedy research and development advances, rise in demand for gene therapies, switching of pharmaceutical market towards biological products, and increasing approvals of nucleic acid therapeutics are factors that drive the market growth. According to the U.S. National clinical research government, there are large number of products based on ASOS and RNA interferences under evaluation and soon will release in the market after approval. Cancer and AIDS are some chronic diseases which shows positive recovery after using nucleic acid therapies. Furthermore, lack of expertise people, high cost of treatments, and very few sources for understanding the human genetics are the factors restraining the market growth.
The upcoming trends of Nucleic Acid Therapeutics Market includes newly developed and approved therapies by the industry leaders to treat single gene defects.
The leading application of Nucleic Acid Therapeutics Market includes monogenetic disorders and multi-genetic disorders.
North America is the largest regional market for Nucleic Acid Therapeutics
Nucleic Acid Therapeutics market is expected to reach $12,224.09 million by 2031, with a CAGR of 11.6% from 2022 to 2031.
Major key players that operate in the global nucleic acid therapeutics market are Agilent Technologies Inc., Alnylam Pharmaceuticals, Inc., Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals, Benetic Biopharma, Inc., Caperna Inc. [Moderna], Copernicus Therapeutics, Genzyme (Sanofi), Ionis Pharmaceuticals, MERCK KGAA, Novartis AG, Phylogica, Protagonist Therapeutics, QIAGEN N.V., Sarepta Therapeutics, Silence Therapeutics plc., and Thermo Fisher Scientific Inc.
The forecast period for Nucleic Acid Therapeutics market is 2022 to 2031
The base year is 2021 in Nucleic Acid Therapeutics market
Loading Table Of Content...
Loading Research Methodology...
